These strategic moves are expected to enhance Lantheus’s radiopharmaceutical capabilities and drive sustained double-digit revenue growth starting in 2026. DEFINITY, the leading ultrasound ...

Lantheus Holdings (NASDAQ ... with potential for multiple commercially approved products in 2026. Definity maintained its market leadership position in ultrasound-enhancing agents during the ...

BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling ...

Pictet Asset Management Holding SA boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 12.1% in ...